Janssen Publishes the Results of Two Studies with Xarelto (rivaroxaban) + Aspirin (Acetylsalicylic Acid) in Patients with CAD and/or PAD
Shots:
- The results from the P-III (COMPASS LTOLE) study & XATOA registry evaluating Xarelto + aspirin in patients (n=27,395 & 5,532) to be published in the ESC. The XATOA registry will also be presented at the ACC 2022
- The results from the COMPASS LTOLE showed Xarelto (2.5mg, BID) + Aspirin (75-100mg OD) treatment for 3yrs. was linked to primary outcome event rate incl. CV death, stroke & MI of 2.35 vs 2.18 in the treatment phase along with an increase in bleeding rated during LTOLE of 1.01 vs 1.67 during the randomized phase
- The results from the XATOA registry showed similar rates of MACE with the COMPASS trial, rates of major adverse limb events (in males) at 3.57 vs 0.19 & the rate of major bleeding at 0.95 vs 1.7 in the COMPASS trial
Ref: PR Newswire | Image: Janseen
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
